نتایج جستجو برای: safacto

تعداد نتایج: 2  

Journal: :iranian journal of blood and cancer 0
p eshghi pediatric congenital hematologic disorders research center, mofid children’s hospital, shahid beheshti university of medical sciences, tehran, iranسازمان اصلی تایید شده: دانشگاه علوم پزشکی شهید بهشتی (shahid beheshti university of medical sciences) h abolghasemi pediatric congenital hematologic disorders research center, mofid children’s hospital, shahid beheshti university of medical sciences, tehran, iranسازمان اصلی تایید شده: دانشگاه علوم پزشکی شهید بهشتی (shahid beheshti university of medical sciences) f malek pediatric congenital hematologic disorders research center, mofid children’s hospital, shahid beheshti university of medical sciences, tehran, iranسازمان اصلی تایید شده: دانشگاه علوم پزشکی شهید بهشتی (shahid beheshti university of medical sciences) m naderi zahedan university of medical sciences, zahedan, iranسازمان اصلی تایید شده: دانشگاه علوم پزشکی زاهدان (zahedan university of medical sciences) y panahi baqiyatallah university of medical sciences, tehran, iranسازمان اصلی تایید شده: دانشگاه علوم پزشکی بقیه الله (baqiyatallah university of medical sciences) b habibpanah comprehensive care center for children with hemophilia, mofid children’s hospital, shahid beheshti university of medical sciences, tehran, iranسازمان اصلی تایید شده: دانشگاه علوم پزشکی شهید بهشتی (shahid beheshti university of medical sciences)

background: considering the increasing number of patients with hemophilia and infrastructure requirements for a comprehensive approach, development of a recombinant factor has become a milestone. the objective of this study was to assess the safety, efficacy and non inferiority of safacto (recombinant factor viii) compared with plasma-derived factor in the treatment of hemophilia a. methods: 10 ...

B Habibpanah, E Fatohlahzadeh, F Gorji, P Eshghi, Y Panahi, F Malek , H Abolghasemi , M Naderi ,

Background: Considering the increasing number of patients with hemophilia and infrastructure requirements for a comprehensive approach, development of a recombinant factor has become a milestone. The objective of this study was to assess the safety, efficacy and non inferiority of Safacto (Recombinant factor VIII) compared with plasma-derived factor in the treatment of hemophilia A. Methods: 10 ...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید